clinicaltrials.gov
RSS-strøm for ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days
Få de siste oppdateringene fra ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days med en gang de kommer.
Nyeste innlegg
Få ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days der du leser
De som følger ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days, følger også
-
Chugai Pharmaceutical: News Releases chugai-pharm.co.jp
-
Regeneron Pharmaceuticals Inc. News Releases investor.regeneron.com
-
What's new ema.europa.eu
Spørsmål
Hva er RSS-adressen til ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days?
Feed-adressen er https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=&lup_d=14&sel_rss=mod14&term=mezagitamab+%28TAK+079%29&recrs=abdf&type=Intr&phase=0124&fund=2&count=10000. Lim den inn i en RSS-leser, eller klikk på Følg nå for å lese den i Feeder.
Hvor ofte publiserer ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days innlegg?
ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days publiserer innlegg sjeldnere enn én gang i uken. Det siste innlegget ble publisert for 13 days siden.
Fungerer RSS-feeden til ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days?
Ja. Feeder sjekket den for about 1 hour siden, og feeden svarte normalt.
Hvordan følger jeg ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days i Feeder?
Klikk på Følg nå, og registrer deg hvis du ikke har en konto ennå. Gratisabonnementet til Feeder lar deg følge opptil 200 feeder på nettet, iPhone og Android. Krever ikke kredittkort.
Følg ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days i Feeder
Gratisabonnementet til Feeder lar deg følge opptil 200 feeder på nettet, iPhone og Android. Krever ikke kredittkort.